Search
forLearn
5 / 801 resultslearn C 13-15 alkane
learn PEG-12 Dimethicone
learn RH410
learn TDM-105795
Research
5 / 296 resultsresearch KRASG12D mutant cells are outcompeted by wild type neighbours in adult pancreas in an EPHA2-dependent manner
Normal cells outcompete and remove mutant cells in the pancreas with the help of the EphA2 receptor.
research Injury suppresses Ras cell competitive advantage through enhanced wild-type cell proliferation
Injury boosts normal skin cell growth, reducing cancer cell advantage.
research Stem cell quiescence acts as a tumour suppressor in squamous tumours
Inactive hair follicle stem cells help prevent skin cancer.
research Activated Kras Alters Epidermal Homeostasis of Mouse Skin, Resulting in Redundant Skin and Defective Hair Cycling
Activating Kras in mouse skin causes excess skin and hair loss.
research Tumor suppressor identity can contribute to heterogeneity of phenotype in hair follicle stem cell‐induced squamous cell carcinoma
The type of tumor suppressor affects the form of skin cancer from hair follicle stem cells.
Community Join
5 / 1000+ resultscommunity GT20029 & KX826 Major Updates from Kintor.
KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.
community Any updates or news on Gt20029?
There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.
community Grey Market GT20029 and Frequency of Application
The conversation is about the potential release of GT20029 on the grey market and concerns about its safety and authenticity. One user advises waiting for the official release by Kintor.
community Has anyone actually seen good results on KX-826?
community GT20029 Anageninc Market Availability
The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.